<DOC>
	<DOC>NCT01107743</DOC>
	<brief_summary>In this survey, to collect the safety and efficacy information of Amlodipine /Atorvastatin (Caduet® Combination Tablets) in daily medical practice will be examined. In addition, the necessity of special Investigation and post-marketing clinical studies will be examined, while investigating unexpected adverse drug reactions during the survey period and understanding of the status of frequency of adverse drug reactions in daily medical practice.</brief_summary>
	<brief_title>Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)</brief_title>
	<detailed_description>All the subjects whom an investigator prescribes the first Amlodipine /Atorvastatin (Caduet®) Combination Tablets should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Amlodipine, atorvastatin drug combination</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Male or Female subjects intend to treat their cardiovascular disease who are prescribed Amlodipine /Atorvastatin (Caduet®) Combination Tablets by their Physicians Subjects who have been prescribed Amlodipine /Atorvastatin (Caduet®) Combination Tablets before.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Angina pectoris</keyword>
	<keyword>Hypercholesterolemia</keyword>
	<keyword>Familial hypercholesterolemia</keyword>
	<keyword>Japanese</keyword>
	<keyword>caduet</keyword>
	<keyword>Regulatory Post Marketing Commitment Plan</keyword>
</DOC>